News

NeurAxon, Inc. to Present at the BIO National Venture Conference April 1, 2009

WALTHAM, Mass.  March 27, 2009 –NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the BIO National Venture Conference taking place March 31 – April 1, 2009 in Boston, MA.

The NeurAxon presentation will be delivered on Wednesday, April 1, 2009 at 10:35am Eastern Time at the Sheraton Boston Hotel.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel, proprietary pain therapeutics, including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in development for acute migraine.

About NeurAxon Inc.
NeurAxon Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Contact:
Chris Erdman
MacDougall Biomedical Communications
781-235-3060